KalVista Pharmaceuticals faces delays from the U.S. Food and Drug Administration as it looks to get approval for its new drug application for sebetralstat, a treatment for hereditary angioedema.

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

The FDA has approved a new pill called Widaplik, which combines three drugs – telmisartan, amlodipine, and indapamide – to treat adults who have high blood pressure.

The Omega-3 Supplements Market is expected to reach at a CAGR of 9.59% during the forecast period 2025-2032. The Omega-3 Supplements Market is booming, driven by rising health awareness, increasing ...

College of Pharmacy, Jouf University, Sakaka, Aljouf 2014, Saudi Arabia ...

Generally, Medicare Part D and Part C plans that include drug coverage should cover simvastatin or other commonly prescribed cholesterol medications.

Dr. Willerson: The LDLs were less than 130 mg/dl. Dr. Hutter ... there were no bad side effects from the rosuvastatin? Dr. Willerson: Right. Dr. Shah: It was pretty remarkable how well tolerated ...

Simvastatin 10 mg/d; RSV 5: Rosuvastatin 5 mg/d; RSV 40: Rosuvastatin 40 mg/d; RSV 20: Rosuvastatin 20 mg/d; RSV 10: Rosuvastatin 10 mg/d. To the best of our knowledge, this is the first study to ...

The mean age of patients was 14.8 years, and mean baseline LDL-C was 272 mg/dL. The placebo-adjusted mean (95% CI) percentage change in LDL-C from baseline to day 330 was −33.3% (−59.2% to −7.3%). Six ...